Clinical

Contributor: COVID-19 Vaccine May Not Be the Ultimate Panacea

September 15, 2020

We should look forward to a safe, effective vaccine for coronavirus disease 2019 (COVID-19) but not expect it to be the ultimate panacea.

25% of Patients With CLL See Disease Flare When Ibrutinib Therapy Pauses

September 15, 2020

Ibrutinib can lead to side effects, causing some physicians to consider reducing the dose or temporarily halting therapy, but that risks disease flares, a new study finds.

Tyrosine Kinase Inhibitor Shows Positive Results in Slowing Slide to MS Disability

September 13, 2020

The drug, mastinib, reduced the chance of a confirmed disability progression by 37% in phase 2b/3 study results.

Choosing the Right MS Treatment by Customizing Therapy to the Individual

September 13, 2020

With more multiple sclerosis (MS) treatments becoming available, it is now possible to better personalize approaches, explained speakers during a session at MSVirtual 2020: 8th Joint ACTRIMS-ECTRIMS Meeting.

Siponimod Delays Disability, Benefits Cognition, Analysis Shows

September 12, 2020

Post hoc data from 2 late-stage studies about siponimod, sold as Mayzent by Novartis, illustrated improved cognitive processing speed and delayed time to disability in multiple sclerosis.

Real-World Study: Dupilumab for Atopic Dermatitis More Effective Than Clinical Trial Results

September 12, 2020

The broadest real-life study of dupilumab in atopic dermatitis (AD) found significant improvements in adults with moderate to severe AD that were even greater than the results reported in clinical trials.

Researchers Detail Treatment Challenges in Primary Progressive MS

September 12, 2020

A minority of patients with multiple sclerosis (MS) have primary progressive disease, and it has few treatment options.

Study Highlights Prevalence of Comorbid Autoimmune Diseases, T1D in Pediatric Populations

September 09, 2020

In recent years, the number of children diagnosed with additional autoimmune diseases accompanying type 1 diabetes (T1D) has increased, according to a study published in Frontiers in Endocrinology.

Dr Anthony Fauci Discusses the Systemic Effects of COVID-19

September 07, 2020

While coronavirus disease 2019 (COVID-19) is largely a respiratory disease, it is actually a systemic disease that has a wide range of effects and postinfection sequelae that aren’t yet fully known, said Anthony S. Fauci, MD, director of the National Institute of Allergy and Infectious Diseases.

Improved Treatment Options for SMA Present New Opportunities, Challenges

September 05, 2020

There are now multiple therapeutic options available for spinal muscular atrophy (SMA), a disease once considered incurable; however, there remains a need for additional treatments and better ways to predict treatment response.